Nektar Therapeutics

LSE:0UNL Stock Report

Market Cap: US$193.7m

Nektar Therapeutics Future Growth

Future criteria checks 1/6

Nektar Therapeutics's earnings are forecast to decline at 6.1% per annum while its annual revenue is expected to grow at 11.8% per year. EPS is expected to grow by 7.1% per annum. Return on equity is forecast to be -191.8% in 3 years.

Key information

-6.1%

Earnings growth rate

7.1%

EPS growth rate

Pharmaceuticals earnings growth19.6%
Revenue growth rate11.8%
Future return on equity-191.8%
Analyst coverage

Good

Last updated19 Nov 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

LSE:0UNL - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202683-193-198-1537
12/31/202584-174-170-1427
12/31/2024100-154-111-1327
9/30/202493-168-178-177N/A
6/30/202493-177-175-175N/A
3/31/202490-176-189-189N/A
12/31/202390-276-193-193N/A
9/30/202388-294-204-203N/A
6/30/202388-307-245-244N/A
3/31/202389-415-269-267N/A
12/31/202292-368-310-304N/A
9/30/202295-454-409-398N/A
6/30/202296-525-430-416N/A
3/31/2022103-491-440-424N/A
12/31/2021102-524-428-413N/A
9/30/2021100-495-371-360N/A
6/30/2021105-474-321-311N/A
3/31/2021126-429-322-312N/A
12/31/2020153-444-321-313N/A
9/30/2020163-439-349-340N/A
6/30/2020163-429-368-356N/A
3/31/2020137-460-347-326N/A
12/31/2019115-441-355-329N/A
9/30/2019121-427-352-321N/A
6/30/2019119-424-352-324N/A
3/31/20191,184657671690N/A
12/31/20181,193681704718N/A
9/30/20181,249746747755N/A
6/30/20181,374903N/A920N/A
3/31/2018321-129N/A-98N/A
12/31/2017308-97N/A-80N/A
9/30/2017250-105N/A-52N/A
6/30/2017133-209N/A-173N/A
3/31/2017131-198N/A-128N/A
12/31/2016165-154N/A-117N/A
9/30/2016167-165N/A-140N/A
6/30/2016191-130N/A-126N/A
3/31/2016181-134N/A-160N/A
12/31/2015231-81N/A-73N/A
9/30/2015211-73N/A-23N/A
6/30/20152846N/A-55N/A
3/31/201529026N/A-16N/A
12/31/2014201-54N/A-142N/A
9/30/2014212-56N/A-64N/A
6/30/2014140-143N/A-37N/A
3/31/2014146-153N/A-63N/A
12/31/2013149-162N/A-39N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 0UNL is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 0UNL is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 0UNL is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 0UNL's revenue (11.8% per year) is forecast to grow faster than the UK market (3.5% per year).

High Growth Revenue: 0UNL's revenue (11.8% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 0UNL is forecast to be unprofitable in 3 years.

Discover growth companies

7D

1Y

7D

1Y

7D

1Y